Avadel's phase 3 REVITALYZ trial of once-nightly sodium oxybate (Lumryz) for idiopathic hypersomnia has completed enrollment. Clinical results are expected in Q2 2026.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
REVITALYZ (NCT06525077) Trial Name
Sodium Oxybate (Lumryz) Drug
Idiopathic Hypersomnia Condition
Once-Nightly Dosing
Q2 2026 Expected Results
Phase 3 trial phase